We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Tomotherapy Incorporated (MM) | NASDAQ:TOMO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.35 | 0 | 01:00:00 |
Leading radiosurgery systems maker Accuray Incorporated (ARAY) has chosen data management and data protection solutions provider Overland Storage (OVRL) to boost the data storage capabilities of its radiosurgery systems.
The California-based company has selected Overland’s SnapServer N2000 storage solution to augment the data storage capacity of its popular CyberKnife robotic radiosurgery systems, which has been already used to treat more than 100,000 patients globally.
During treatment using CyberKnife, a session can generate 250-500 megabytes (MB) of patient treatment data. With each patient typically requiring one to five treatments, data storage becomes a critical issue.
To load a treatment plan into the CyberKnife system, clinics have to rapidly transfer 250-750MB of data. The SnapServer N2000 enables fast data transfer and increases data availability for their clinical users.
Accuray is a global leader in the field of radiosurgery and provides a non-surgical treatment option for patients diagnosed with cancer. The company continues to enjoy healthy demand for the CyberKnife systems.
CyberKnife continues to gain significant traction in the global medical communities, thereby boosting Accuray’s sales. The company is pursuing a number of strategies to expand CyberKnife’s adoption.
Accuray’s CyberKnife system boasts of a technology that differentiates it from traditional treatments. CyberKnife, a non-invasive alternative to conventional surgery, is the first and only commercially available intelligent robotic radiosurgery system designed to treat solid tumors anywhere in the body. Patients can be treated with CyberKnife without anesthesia and without the risks and complications inherent in traditional surgery.
Accuray is expected to benefit from the recent recovery in hospital capital equipment spending. Moreover, the company is well placed to bolster its foothold in the radiation oncology market with its acquisition of rival TomoTherapy (TOMO).
However, Accuray remains susceptible to reimbursement uncertainties surrounding its products and its CyberKnife system faces stiff challenges from competitive product offerings of Varian Medical (VAR). We are currently Neutral on Accuray.
1 Year Tom Online Chart |
1 Month Tom Online Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
